208 related articles for article (PubMed ID: 34347972)
21. IL-17 mediates resistance to anti-VEGF therapy.
Maniati E; Hagemann T
Nat Med; 2013 Sep; 19(9):1092-4. PubMed ID: 24013745
[TBL] [Abstract][Full Text] [Related]
22. Resistance and escape from antiangiogenesis therapy: clinical implications and future strategies.
Bottsford-Miller JN; Coleman RL; Sood AK
J Clin Oncol; 2012 Nov; 30(32):4026-34. PubMed ID: 23008289
[TBL] [Abstract][Full Text] [Related]
23. Intussusceptive angiogenesis as a key therapeutic target for cancer therapy.
Saravanan S; Vimalraj S; Pavani K; Nikarika R; Sumantran VN
Life Sci; 2020 Jul; 252():117670. PubMed ID: 32298741
[TBL] [Abstract][Full Text] [Related]
24. A Decade of Experience in Developing Preclinical Models of Advanced- or Early-Stage Spontaneous Metastasis to Study Antiangiogenic Drugs, Metronomic Chemotherapy, and the Tumor Microenvironment.
Kerbel RS
Cancer J; 2015; 21(4):274-83. PubMed ID: 26222079
[TBL] [Abstract][Full Text] [Related]
25. The multifaceted activity of VEGF in angiogenesis - Implications for therapy responses.
Moens S; Goveia J; Stapor PC; Cantelmo AR; Carmeliet P
Cytokine Growth Factor Rev; 2014 Aug; 25(4):473-82. PubMed ID: 25169850
[TBL] [Abstract][Full Text] [Related]
26. The Challenges of Modeling Drug Resistance to Antiangiogenic Therapy.
Mastri M; Rosario S; Tracz A; Frink RE; Brekken RA; Ebos JM
Curr Drug Targets; 2016; 17(15):1747-1754. PubMed ID: 26648063
[TBL] [Abstract][Full Text] [Related]
27. Anti-angiogenesis in cancer therapeutics: the magic bullet.
Oguntade AS; Al-Amodi F; Alrumayh A; Alobaida M; Bwalya M
J Egypt Natl Canc Inst; 2021 Jul; 33(1):15. PubMed ID: 34212275
[TBL] [Abstract][Full Text] [Related]
28. Combination therapy in cancer: effects of angiogenesis inhibitors on drug pharmacokinetics and pharmacodynamics.
Fuso Nerini I; Cesca M; Bizzaro F; Giavazzi R
Chin J Cancer; 2016 Jun; 35(1):61. PubMed ID: 27357621
[TBL] [Abstract][Full Text] [Related]
29. Hypoxia-Inducible PIM Kinase Expression Promotes Resistance to Antiangiogenic Agents.
Casillas AL; Toth RK; Sainz AG; Singh N; Desai AA; Kraft AS; Warfel NA
Clin Cancer Res; 2018 Jan; 24(1):169-180. PubMed ID: 29084916
[No Abstract] [Full Text] [Related]
30. An interleukin-17-mediated paracrine network promotes tumor resistance to anti-angiogenic therapy.
Chung AS; Wu X; Zhuang G; Ngu H; Kasman I; Zhang J; Vernes JM; Jiang Z; Meng YG; Peale FV; Ouyang W; Ferrara N
Nat Med; 2013 Sep; 19(9):1114-23. PubMed ID: 23913124
[TBL] [Abstract][Full Text] [Related]
31. Glioblastoma angiogenesis: VEGF resistance solutions and new strategies based on molecular mechanisms of tumor vessel formation.
Takano S
Brain Tumor Pathol; 2012 Apr; 29(2):73-86. PubMed ID: 22218709
[TBL] [Abstract][Full Text] [Related]
32. The only way out is in: a deeper understanding of anti-VEGF therapy escape mechanisms offers possibilities for more effective antiangiogenic treatment.
Ottenhausen M; Bodhinayake I; Boockvar JA
Neurosurgery; 2013 Dec; 73(6):N9. PubMed ID: 24257344
[No Abstract] [Full Text] [Related]
33. Mechanisms of and strategies for overcoming resistance to anti-vascular endothelial growth factor therapy in non-small cell lung cancer.
Huang Y; Carbone DP
Biochim Biophys Acta; 2015 Apr; 1855(2):193-201. PubMed ID: 25598052
[TBL] [Abstract][Full Text] [Related]
34. Personalising and targeting antiangiogenic resistance: a complex and multifactorial approach.
Bueno MJ; Mouron S; Quintela-Fandino M
Br J Cancer; 2017 Apr; 116(9):1119-1125. PubMed ID: 28301873
[TBL] [Abstract][Full Text] [Related]
35. Combination of antiangiogenesis with chemotherapy for more effective cancer treatment.
Ma J; Waxman DJ
Mol Cancer Ther; 2008 Dec; 7(12):3670-84. PubMed ID: 19074844
[TBL] [Abstract][Full Text] [Related]
36. New insights into antiangiogenic therapy resistance in cancer: Mechanisms and therapeutic aspects.
Huang M; Lin Y; Wang C; Deng L; Chen M; Assaraf YG; Chen ZS; Ye W; Zhang D
Drug Resist Updat; 2022 Sep; 64():100849. PubMed ID: 35842983
[TBL] [Abstract][Full Text] [Related]
37. Targeting tumor micro-environment for design and development of novel anti-angiogenic agents arresting tumor growth.
Gacche RN; Meshram RJ
Prog Biophys Mol Biol; 2013 Nov; 113(2):333-54. PubMed ID: 24139944
[TBL] [Abstract][Full Text] [Related]
38. DLL4-Notch signaling mediates tumor resistance to anti-VEGF therapy in vivo.
Li JL; Sainson RC; Oon CE; Turley H; Leek R; Sheldon H; Bridges E; Shi W; Snell C; Bowden ET; Wu H; Chowdhury PS; Russell AJ; Montgomery CP; Poulsom R; Harris AL
Cancer Res; 2011 Sep; 71(18):6073-83. PubMed ID: 21803743
[TBL] [Abstract][Full Text] [Related]
39. Expression of vascular endothelial growth factor (VEGF) and VEGF receptors in tumor angiogenesis and malignancies.
Pradeep CR; Sunila ES; Kuttan G
Integr Cancer Ther; 2005 Dec; 4(4):315-21. PubMed ID: 16282508
[TBL] [Abstract][Full Text] [Related]
40. The Sabotaging Role of Myeloid Cells in Anti-Angiogenic Therapy: Coordination of Angiogenesis and Immune Suppression by Hypoxia.
Li C; Liu T; Bazhin AV; Yang Y
J Cell Physiol; 2017 Sep; 232(9):2312-2322. PubMed ID: 27935039
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
